Litcius/Paper detail

The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Ana Gómez Rueda, Álvaro Taus, Rosa Álvarez, Reyes Bernabé, L.E. Chara, M. López-Brea, Laia Vilà, Maria Ángeles Sala González, Anabel del Barrio Díaz Aldagalán, B. Esteban Herrera, Rafael López Castro, R. Álvarez Cabellos, Marta Doménech, Sandra Falagán, Alberto Moreno-Vega, Carlos Aguado, Andrés Barba, M.T. Delgado Ureña, Dolores Isla, Lorena Hernandez, José Luis Fírvida Pérez, Óscar Juan, Bartomeu Massutí, Xabier Mielgo-Rubio, Ana Laura Ortega Granados, Sílvia Catot, Manuel Dómine, Corina Escoín-Pérez, Francisco García Navalón, Ignacio Gil‐Bazo, Silvia Muñoz, Delvys Rodríguez‐Abreu, Rosa María Villatoro Roldán, Guillermo Alonso-Jáudenes Curbera, Luis León‐Mateos, Airam Padilla, Alfredo Paredes Lario, J.M. Sánchez-Torres, Pilar Garrido, the Spanish Lung Cancer Group

2024Clinical & Translational Oncology10 citationsDOI

Topics & Concepts

DurvalumabMedicinePneumonitisDiscontinuationInternal medicineClinical endpointChemoradiotherapynon-small cell lung cancer (NSCLC)Hazard ratioRetrospective cohort studyAdverse effectLung cancerSurgeryOncologyRadiation therapyCancerLungClinical trialConfidence intervalNivolumabImmunotherapyA549 cellCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations